Looking for Sense in the Italian Antitrust Authority Decision in the Pfizer Xalatan Case

Daniela Ampollini, Jul 27, 2012

The January 2012 decisionĀ of the Italian Antitrust Authority (“IAA”) in the Pfizer case, involving Pfizer’s actions to counter the marketing of generic versions of its product Xalatan, has given rise to a debate which has hardly appeased. Many commentators have already provided their impression from a competition law perspective. I, a patent lawyer, will try to provide mine, starting from the meaning and function of the patent law categories involved.

Links to Full Content

 

ACCESS TO THIS ARTICLE IS RESTRICTED TO SUBSCRIBERS

Please sign in or join us
to access premium content!